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Small bowel transplantation is the definitive treatment for patients who have undergone extensive intestinal resection and are surviving on total parenteral nutrition. After many experimental studies and the introduction of new immunosuppressive drugs, small bowel transplantation was first performed in humans in 1985.1-3 Cyclosporin A was the first drug used, while the clinical demonstration of the superior therapeutic efficacy of FK506 ushered in the current era of small bowel and multivisceral transplantation. 4 The largest reported series describes 21 adults and 22 children, including patients who have received an isolated intestinal graft, a combined liver-small bowel graft, or multivisceral grafts.5 Seven children with short bowel syndrome have received a major histocompatibility class (MHC) incompatible small bowel allograft since 1987. In five patients, the grafts were provided by paediatric or adult donors, and in two patients by anencephalic neonates. In all patients, the distal part of the graft was left as an enterostomy for at least the first three months, allowing sequential biopsy specimens and thus close histological and immunohistochemical follow up of the graft. Despite heavy immunosuppressive treatment, including cyclosporin, episodes of early acute rejection occurred in the first five patients, leading to removal of the grafts between 23 days and 17 months after transplantation. In contrast, no episode of early acute rejection occurred in the two last children, one of which still has a functional graft five years after transplantation. 6 7 This study aimed to provide a detailed analysis of the immunohistochemical changes accompanying histological rejection and to define immunohistological criteria useful for the prediction of rejection or to follow up treatment of rejection, or both. We have studied the numbers and phenotype of T cells, the numbers of natural killer (NK) cells and macrophages, and the expression of the CD25 and HLA-DR antigens. We also examined the endothelial expression of three adhesion molecules -intracellular adhesion molecule-i (ICAM-1), vascular cell adhesion molecule-i (VCAM-1), and E-selectin -which are induced on endothelial cells by inflammatory cytokines and which play a key role in leukocyte migration in normal and inflammatory conditions.8
In addition, immunohistochemical parameters were compared in the two groups of children to identify possible differences which might explain their different evolution and the absence of early acute rejection in the two patients who received a neonatal intestine. In patients 6 and 7, early rejection was not observed. Enteral feeding was restarted on days 30 and 20 respectively. In patient 6, rejection episodes started only at the beginning of the 5th month, a few days after intestinal continuity was re-established; these were poorly controlled by immunosuppressive therapy and led to graft removal 7 months after transplantation. In patient 7, four mild episodes of delayed acute rejection occurred between 3 and 19 months (days 82, 123, 220; 19th month). All episodes were controlled by the immunosuppressive treatment (respectively OKT3, anti-interleukin 2 receptor (anti-rIL2), ALG). Digestive continuity could be reestablished 8 months after transplantation. Since the 26th month after transplantation, the child has been fed entirely orally.7 Six years after grafting, she receives cyclosporine A, azathioprine ( cell infiltration in the lamina propria, villous atrophy, and neutrophil or eosinophil polymorphs, as indicated in Table II . Histological scores of 2-4 were considered as mild rejection (R1); scores of 5-6 indicated moderate rejection (R2), and scores of 7-10 severe rejection (R3) (Figs 1 and 2 ).
Chronic rejection, observed in a single case (patient 2), was characterised by total villous atrophy and mucosal atrophy. In contrast with acute rejection, there was no crypt necrosis: crypts were short but contained numerous mitoses. In addition, there was severe endarteritis of submucosal vessels and extensive fibrosis leading to a massive shortening of the graft. The epithelium and lamina propria were infiltrated by mononuclear cells. the crypts. In group 2, CD3+LPL were rare and scattered. During the first days after transplantation, the numbers of LPL remained moderate in group 1, and no change was observed in group 2. No foci of CD8 cells were present on biopsy specimens taken at times unrelated to a rejection episode; CD25+ cells were rare and were detected only within lymphoid follicles.
Biopsies performed 1 to 5 days before acute histological rejection (n= 5) were characterised by the appearance of focal pericryptic infiltrates (fig 3) . These pericryptic infiltrates were mainly composed of CD3+TCRcxa3+ lymphocytes, and contained a high proportion of CD8+ cells (at least 50%). Numerous cells expressing CD25 (rIL2 receptor) were observed in the 3 samples taken two days before histological rejection in the pericryptic area. In the other samples, CD25 + cells remained scarce.
During episodes of acute rejection (n= 13), the lamina propria contained multifocal (n=4) or diffuse (n=3) CD3+TCRo3+ infiltrates in group 1 patients, and focal (n=4) to multifocal (n=2) infiltrates which predominated around the crypts in group 2. Foci of CD8+ cells surrounding damaged crypts were observed in 11 biopsy specimens, and numerous cells expressing CD25 were present in nine samples beneath and around the crypts. With successful treatment of rejection, the numbers of LPL decreased in all cases, with disappearance of both CD25+ cells and of CD8+ foci.
The single case of chronic rejection was associated with a diffuse infiltration of the lamina propria by CD33+TCRoa + cells, many ofthem CD8+ cells. CD25+ cells were numerous and distributed evenly in the mucosa.
As could be expected, however, an increase in the density of lamina propria T cells was not restricted to rejection but was also observed in biopsy specimens taken in two patients with evidence of continuing CMV infection. As during rejection, the lamina propria infiltrate contained both CD4+ and CD8+ cells. No CD25+ cells were observed but the frozen tissue sections examined did not contain any viral inclusions.
NON-SPECIFIC EFFECTOR CELLS
On day 0, CD68+ HLA-DR+ macrophages were present in both groups of patients; they were distributed both in villous and pericryptic lamina propria. Their density increased around damaged crypts during rejection. NK cells, as revealed by the CD56 marker, were never observed, during rejection.
INCREASED HLA-DR EXPRESSION ON CRYPT EPITHELIAL CELLS DURING REJECTION
HLA-DR expression at day 0 in group 1 patients was diffuse on the villous epithelium and focal on the crypts (Fig 4A) . In contrast, in the two group 2 patients, HLA-DR antigens were not detected on either surface or crypt epithelium (Fig 4B) . In patient 6 ICAM-1 was strongly expressed at day 0, on many deep and superficial mucosal vessels in all patients. Weak to moderate VCAM-1 expression was observed on some deep and supefficial mucosal vessels in patients 2, 6, and 7: no VCAM-1 expression was detected in the other grafts. Occasional vessels expressing E-selectin were found in the deep mucosa in all patients, with a staining score of 1. After day 0, expression of ICAM-1 remained strong on most vessels and no significant change could be detected during rejection. Surprisingly, VCAM-1 was either absent or detected only on rare vessels, even during rejection. In contrast, during rejection, E-selectin appeared on vessels in the superficial lamina propria and the staining scores for E-selectin increased from 1 to 2-3 in all patients. With successful treatment of rejection, E-selectin staining scores decreased from 2-3 to 1, and labelling of superficial vessels disappeared. Although changes in E-selectin expression were evident during rejection, they were not detected in the biopsy specimens performed a few days before rejection.
It is worth noting that ICAM-1 and VCAM-1 were expressed on numerous lamina propria large cells in all biopsy specimens. In contrast, ICAM-1, VCAM-1, and E-selectin were not detected on epithelial cells.
Discussion
The analysis of 85 intestinal biopsy specimens performed in seven children to follow up intestinal MHC-mismatched allografts has allowed the precise description of immunohistochemical changes accompanying acute intestinal rejection in humans. One constant immunohistochemical feature was the presence of pericryptic infiltrates of CD3+TCRotp+T cells and CD68+ macrophages. The clusters of CD8+ lymphocytes and of small or large CD25 + cells in these infiltrates, not observed in normal intestine, were particularly characteristic of rejection. In contrast with a mouse model of fetal intestinal allograft rejection, 1 ' there was only an inconstant increase in the number of IEL. Moreover, IEL counts remained at a low level in 4 of 7 cases of delayed acute rejection. The constant presence of clusters of CD8+ cells around and inside necrotic crypts suggests that the latter cells are cytotoxic T cells and play an important role in the epithelial destruction characteristic of intestinal rejection, a hypothesis supported by the detection of mRNA encoding for serine esterase B in the pericryptic areas of an intestinal graft undergoing acute rejection.'2 In the late phases of intestinal rejection, T cell infiltration involved the whole mucosa and was associated with massive recruitment of nonspecific effector cells which outnumbered T cells. These included activated macrophages (CD68+, DR+, CD25+) and polymorphonuclear cells but no NK cells, at least as detected by the CD56 marker. These observations are in keeping with studies of rejected renal allografts.13 They are also comparable to the observations made in a rat model in which acute rejection of an intestinal allograft was first associated with a significant increase in the number of lamina propria TCRotp+CD8o+CD8o43+ lymphocytes of recipient origin and secondarily with a strong infiltration by macrophages and polymorphonuclear cells. '4 In the present study, chronic rejection was observed only once. It differed markedly from both early or delayed acute rejection. As in chronic rejection processes affecting other organs, there was a severe endarteritis and extensive fibrosis. In contrast to acute rejection, there was striking villous atrophy and even mucosal atrophy but no crypt necrosis. Infiltration by CD8+ T cells was diffuse and the number of IEL extremely high.
During rejection, the appearance of pericryptic activated T cells was always associated with increased expression of HLA-DR antigens on crypt enterocytes. This enhanced expression is likely to be due to the production by activated T was suggested that the appearance of macrophages in the submucosa is a good indicator of continuing rejection.3 However, in our patients, the biopsies were superficial in order to avoid any risk of perforation and the submucosa was not visible, thus preventing assessment of the presence of submucosal macrophages. Immunohistochemistry was also useful for monitoring rejection treatment. Indeed, histological improvement is slow and can take several weeks when destruction has been extensive. In contrast, in cases where rejection treatment was successful, immunohistochemistry showed a marked decrease in the number of lamina propria T cells and the disappearance of pericryptic foci of CD8+ cells within two days and the disappearance of HIA-DR expression on crypts and of E-selectin on superficial vessels within a week. This immunohistochemical improvement was not observed in cases of uncontrolled rejection.
Finally, the most intriguing observation was the different evolution of grafts provided by neonatal and older donors. The difference could not be easily ascribed to the treatment, which was comparable in most patients. The young age of the recipients may have contributed to better graft tolerance. Alternatively, it is possible that the neonatal intestine is less immunogenic. However, the density of CD68+ macrophages, capable of presenting donor antigens to recipient T cells, was comparable in the lamina propria of neonates and of older donors. Nor was there a significant difference in the endothelial expression of three of the adhesion molecules able to recruit recipient leukocytes and thus to favour sensitisation of recipient leukocytes to donor antigens. A lesser immunogenicity of the neonatal allografts may be related to a distinctive expression of other adhesion molecules not tested in this study, such as the B7 molecules which participate in the induction of the immune response22 or the mucosal adressin which is involved in lymphocyte homing in intestinal mucosa.23 It may also be related to a distinct immunogenicity of the epithelium. Indeed, the main differences between neonatal intestines and intestines provided by older donors were the lower numbers of IELs and the lack of expression of MHC class II antigens by epithelial cells. Such findings could be expected. In 
